-
EP3773902
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3773902
| EP3773902 - BRAIN NATRIURETIC PEPTIDE ENGRAFTED ANTIBODIES [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 26.05.2023 Database last updated on 19.10.2024 | |
| Former | Request for examination was made Status updated on 15.01.2021 | ||
| Former | The international publication has been made Status updated on 19.10.2019 | ||
| Former | unknown Status updated on 17.04.2019 | Most recent event Tooltip | 03.05.2024 | Change - applicant | published on 05.06.2024 [2024/23] | Applicant(s) | For all designated states Boehringer Ingelheim International GmbH Binger Strasse 173 55216 Ingelheim am Rhein / DE | [2024/23] |
| Former [2021/07] | For all designated states Bayer Aktiengesellschaft Kaiser-Wilhelm-Allee 1 51373 Leverkusen / DE | Inventor(s) | 01 /
BROCKSCHNIEDER, Damian Kaiserstr. 48c 42781 Haan / DE | 02 /
TEBBE, Jan Am Alten Stellwerk 16 50733 Köln / DE | 03 /
WILMEN, Andreas Liebermannstrasse 12 50933 Köln / DE | 04 /
WUNDER, Frank Schwarzer Weg 251 42117 Wuppertal / DE | [2021/07] | Representative(s) | BIP Patents c/o Bayer Intellectual Property GmbH Alfred-Nobel-Straße 50 40789 Monheim am Rhein / DE | [N/P] |
| Former [2021/07] | BIP Patents c/o Bayer Intellectual Property GmbH Alfred-Nobel-Straße 10 40789 Monheim am Rhein / DE | Application number, filing date | 19716170.6 | 10.04.2019 | [2021/07] | WO2019EP59101 | Priority number, date | EP20180167106 | 12.04.2018 Original published format: EP 18167106 | [2021/07] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2019197475 | Date: | 17.10.2019 | Language: | EN | [2019/42] | Type: | A1 Application with search report | No.: | EP3773902 | Date: | 17.02.2021 | Language: | EN | The application published by WIPO in one of the EPO official languages on 17.10.2019 takes the place of the publication of the European patent application. | [2021/07] | Search report(s) | International search report - published on: | EP | 17.10.2019 | Classification | IPC: | A61P9/12, C07K14/58, C07K16/00, C07K19/00 | [2021/07] | CPC: |
C07K16/00 (EP,IL,KR,US);
A61K38/00 (US);
A61P9/04 (KR,US);
A61P9/12 (EP,IL,US);
C07K14/58 (EP,IL,KR,US);
A61K2039/505 (EP,IL,KR,US);
C07K2317/21 (US);
C07K2317/24 (US);
C07K2317/52 (EP,IL,KR);
C07K2317/53 (EP,IL,KR);
C07K2317/565 (KR,US);
C07K2317/567 (EP,IL,KR);
C07K2317/94 (EP,IL,KR,US);
C07K2318/10 (EP,IL,KR,US);
C07K2319/00 (EP,IL,KR);
C07K2319/31 (US)
(-)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2021/07] | Extension states | BA | 12.11.2020 | ME | 12.11.2020 | Title | German: | NATRIURETISCHE PEPTIDGEPFROPFTE ANTIKÖRPER IM GEHIRN | [2021/07] | English: | BRAIN NATRIURETIC PEPTIDE ENGRAFTED ANTIBODIES | [2021/07] | French: | ANTICORPS GREFFÉS DE PEPTIDES NATRIURÉTIQUES CÉRÉBRAUX | [2021/07] | Entry into regional phase | 12.11.2020 | National basic fee paid | 12.11.2020 | Designation fee(s) paid | 12.11.2020 | Examination fee paid | Examination procedure | 12.11.2020 | Examination requested [2021/07] | 12.11.2020 | Date on which the examining division has become responsible | 31.05.2021 | Amendment by applicant (claims and/or description) | 31.05.2023 | Despatch of a communication from the examining division (Time limit: M06) | 08.12.2023 | Reply to a communication from the examining division | Fees paid | Renewal fee | 15.04.2021 | Renewal fee patent year 03 | 20.03.2022 | Renewal fee patent year 04 | 14.03.2023 | Renewal fee patent year 05 | 30.04.2024 | Renewal fee patent year 06 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [A]WO02078612 (PURDUE PHARMA LP [US], et al); | [I]US2004253242 (BOWDISH KATHERINE S [US], et al); | [ID]WO2005082004 (ALEXION PHARMA INC [US], et al); | [AD]WO2008154226 (BOEHRINGER INGELHEIM INT [DE], et al); | [A]WO2010054007 (FABRUS LLC [US], et al); | by applicant | US4399216 | US4510245 | US4634665 | US4816397 | US4968615 | US5168062 | US5179017 | WO0006568 | WO0006569 | WO0119355 | WO0119776 | WO0119778 | WO0119780 | WO0242301 | WO02070462 | WO02070510 | WO03095451 | WO2005060642 | WO2005082004 | WO2006107124 | WO2008079995 | WO2008136611 | WO2008154226 | US7521424 | WO2010105770 | WO2010117760 | US2010310561 | WO2011104322 | WO2011147809 | WO2012004258 | WO2012028647 | EP2432489 | WO2012059549 | US2014148390 | US9193777 | WO2016071212 |